Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 246 citing articles:

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Pharmacological Reviews (2018) Vol. 70, Iss. 2, pp. 197-245
Open Access | Times Cited: 306
Advances in the management of chronic insomnia
Margaret Kay-Stacey, Hrayr Attarian
BMJ (2016), pp. i2123-i2123
Closed Access | Times Cited: 144
Sleep Medicine: Insomnia and Sleep.
Pradeep C. Bollu, Harleen Kaur
PubMed (2019) Vol. 116, Iss. 1, pp. 68-75
Closed Access | Times Cited: 128
Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews
Patricia Rios, Roberta Cardoso, Deanna E. Morra, et al.
Systematic Reviews (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 111
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
Yves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
Annals of Neurology (2020) Vol. 87, Iss. 3, pp. 347-356
Closed Access | Times Cited: 110
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Insomnia in older adults: A review of treatment options
Roberto León-Barriera, Margaret Chaplin, Jasleen Kaur, et al.
Cleveland Clinic Journal of Medicine (2025) Vol. 92, Iss. 1, pp. 43-50
Open Access | Times Cited: 1
Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians
Gregory M. Asnis, Manju Thomas, Margaret Henderson
International Journal of Molecular Sciences (2015) Vol. 17, Iss. 1, pp. 50-50
Open Access | Times Cited: 90
Suvorexant in insomnia: efficacy, safety and place in therapy
Danielle N. Rhyne, Sarah L. Anderson
Therapeutic Advances in Drug Safety (2015) Vol. 6, Iss. 5, pp. 189-195
Open Access | Times Cited: 74
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Taro Kishi, Shinji Matsunaga, Nakao Iwata
PLoS ONE (2015) Vol. 10, Iss. 8, pp. e0136910-e0136910
Open Access | Times Cited: 72
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Suvorexant
Kunal V. Patel, Anthony V. Aspesi, Kirk E. Evoy
Annals of Pharmacotherapy (2015) Vol. 49, Iss. 4, pp. 477-483
Closed Access | Times Cited: 65
Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59
Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy
Cliff H. Summers, Jazmine D. W. Yaeger, Clarissa D. Staton, et al.
Brain Research (2018) Vol. 1731, pp. 146085-146085
Open Access | Times Cited: 59
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Erin J. Campbell, Nathan J. Marchant, Andrew J. Lawrence
Brain Research (2018) Vol. 1731, pp. 145902-145902
Closed Access | Times Cited: 50
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Andrew Hogyu Han, Caroline R. Burroughs, Evan P. Falgoust, et al.
Health psychology research (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 13
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery
Janet Fallon, Mona Hashemaghaie, Craig A. Peterson, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e091099-e091099
Open Access
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
Sarah L. Anderson, Jessica Norman
Nature and Science of Sleep (2016) Vol. Volume 8, pp. 239-247
Open Access | Times Cited: 44
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Prescriber's Guide
Stephen M. Stahl
(2020)
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top